The most up-to-date SEER surveillance system for pancreatic cancer indicates that the 5-year survival rate is 6.0%. A physician at a local hospital has organized a trial thatrecruits 5,014 pancreatic cancer patients assesses the ability of his newly developedchemotherapy to improve that survival rate. By the end of 5 years of follow up, 376patients of the original 5,014 were still alive. A. What is the 5-year survival rate for the therapy developed in the trial?

B. What is the relative risk in 5-year mortality for the new therapy versus current bestmedical care? Interpret this result.